Itau Unibanco Holding S.A.’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-268
Closed -$6.17K – 537
2023
Q1
$6.17K Hold
268
– – ﹤0.01% 472
2022
Q4
$7.45K Sell
268
-1,130
-81% -$33.6K ﹤0.01% 474
2022
Q3
$43K Sell
1,398
-553
-28% -$18K ﹤0.01% 399
2022
Q2
$57K Buy
1,951
+3
+0.2% +$79 ﹤0.01% 325
2022
Q1
$63K Hold
1,948
– – ﹤0.01% 298
2021
Q4
$88K Buy
1,948
+1,569
+414% +$74.3K ﹤0.01% 227
2021
Q3
$19K Buy
379
+10
+3% +$564 ﹤0.01% 340
2021
Q2
$29K Buy
+369
New +$22.8K ﹤0.01% 265

Other funds holding DNLI

Itau Unibanco Holding S.A.'s DNLI Position: Q2 2023 in Review

Itau Unibanco Holding S.A. sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 268 shares — an estimated $6.17K sold.

Itau Unibanco Holding S.A. first reported a position in DNLI in Q2 2021 and held it in 8 quarters. The position peaked at $88K in Q4 2021. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Itau Unibanco Holding S.A. reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Itau Unibanco Holding S.A. sold 268 Denali Therapeutics shares in Q2 2023, an estimated $6.17K.
  • Itau Unibanco Holding S.A. first reported a position in Denali Therapeutics in Q2 2021 and held it in 8 quarters.
  • Itau Unibanco Holding S.A.'s Denali Therapeutics position peaked at $88K in Q4 2021.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q2 2023, filed 14 Aug 2023.